Long-term posttransplant survival outcome following bridging locoregional therapy in hepatocellular carcinoma patients: A systematic review and meta-analysis.

Aim: Liver transplantation (LT) is essential due to its curative efficacy, but liver-graft shortages have limited its widespread application. Bridging locoregional therapy (LRT) before LT has been performed to prevent tumor progression, and a recent literature review revealed that it is associated with a nonsignificant trend toward better survival outcomes. However, much more information on bridging therapy has become available since then.

Outcomes of direct-acting antivirals in patients with HCV decompensated cirrhosis: a systematic review and meta-analysis.

Background: Direct-acting antivirals (DAA) are effective for chronic hepatitis C virus (HCV) treatment. However, their impact on overall survival (OS), hepatocellular carcinoma (HCC) occurrence, HCC-free survival, and liver function in patients with HCV decompensated cirrhosis remains uncertain. This study aimed to evaluate the effects of DAA treatment on this population.

The detection of hepatocellular carcinoma (HCC) from patients' breath using canine scent detection: a proof-of-concept study.

Unlabelled: Patients with hepatocellular carcinoma (HCC) have poor outcomes as a result of late detection of the disease. We investigated the possibility of using smell detection by dogs for detecting HCC from the breath of patients. Patients whose diagnosis of HCC was confirmed histologically or radiologically according to the American Association for the Study of Liver Diseases criteria had breaths collected using face masks and transported to the study test site.

Advances in Management of Hepatocellular Carcinoma.

Hepatocellular carcinoma (HCC) is the most frequent type of malignant liver tumor and a high impact health problem worldwide. The prevalence of HCC is particularly high in many Asian and African countries. Some HCC patients have no symptoms prior to diagnosis and many of them therefore present at late stage and have a grave prognosis.

Donor outcomes after living donor liver transplantation (LDLT).

Liver transplantation is an accepted management for end stage liver disease, early-stage hepatocellular carcinoma, and acute liver failure. The number of patients with end stage liver disease is growing rapidly. Living Donor Liver Transplantation (LDLT) has become an important alternative to cadaveric organ transplant for patients with end stage liver disease.

Evaluation of donors for living donor liver transplantation (LDLT).

Liver transplantation has been the last resort of definite treatment for decompensate cirrhosis, early-stage of hepatocellular carcinoma, and acute liver failure. Organ shortage is the major obstacle of deceased-donor liver transplantation. Since the first case of living-donor liver transplantation (LDLT), many centers around the world started the LDLT program.

Predictors of relapse to significant alcohol drinking after liver transplantation.

Background: End-stage alcoholic liver disease is common, with many of these patients referred for liver transplantation (LT). Alcohol relapse after LT can have detrimental outcomes such as graft loss and can contribute to a negative public perception of LT.

Objective: To identify factors that predict the recurrence of harmful alcohol consumption after LT.

Expression of integrin-linked kinase is not a useful prognostic marker in resected hepatocellular cancer.

Background: Hepatocellular cancer (HCC) is one of the most common malignancies worldwide, and is known to be associated with a poor prognosis. Unfortunately there are no available reliable markers of prognosis. The aim of this study was to determine whether integrin-linked kinase (ILK) expression correlates with post-resection survival from HCC.

Utilization of a liver allograft from a hepatitis B surface antigen positive donor.

With today's donor organ shortage, enhanced efforts must be made to utilize organs that previously would have been declined. We report a 26-year-old man with chronic hepatitis B virus (HBV) and hepatitis C virus (HCV) coinfection who received a liver transplant from an HBsAg-positive donor. HBV viremia (6,281,185 copies/ml) was seen early posttransplant despite lamivudine prophylaxis, but became negative with addition of adefovir.